334 related articles for article (PubMed ID: 36754548)
1. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis.
Burmester GR; Cohen SB; Winthrop KL; Nash P; Irvine AD; Deodhar A; Mysler E; Tanaka Y; Liu J; Lacerda AP; Palac H; Shaw T; Mease PJ; Guttman-Yassky E
RMD Open; 2023 Feb; 9(1):. PubMed ID: 36754548
[TBL] [Abstract][Full Text] [Related]
2. MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Charles-Schoeman C; Choy E; McInnes IB; Mysler E; Nash P; Yamaoka K; Lippe R; Khan N; Shmagel AK; Palac H; Suboticki J; Curtis JR
RMD Open; 2023 Nov; 9(4):. PubMed ID: 37945286
[TBL] [Abstract][Full Text] [Related]
3. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.
Burmester GR; Stigler J; Rubbert-Roth A; Tanaka Y; Azevedo VF; Coombs D; Lagunes I; Lippe R; Wung P; Gensler LS
Rheumatol Ther; 2024 Apr; ():. PubMed ID: 38683479
[TBL] [Abstract][Full Text] [Related]
4. Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis.
Rubbert-Roth A; Kakehasi AM; Takeuchi T; Schmalzing M; Palac H; Coombs D; Liu J; Anyanwu SI; Lippe R; Curtis JR
Rheumatol Ther; 2024 Feb; 11(1):97-112. PubMed ID: 37982966
[TBL] [Abstract][Full Text] [Related]
5. Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials.
Burmester GR; Winthrop K; Blanco R; Nash P; Goupille P; Azevedo VF; Salvarani C; Rubbert-Roth A; Lesser E; Lippe R; Lertratanakul A; Mccaskill RM; Liu J; Ruderman EM
Rheumatol Ther; 2022 Apr; 9(2):521-539. PubMed ID: 34970731
[TBL] [Abstract][Full Text] [Related]
6. Safety of upadacitinib in Latin American patients with rheumatoid arthritis: an integrated safety analysis of the SELECT phase 3 clinical program.
Kakehasi AM; Radominski SC; Baravalle MD; Palazuelos FCI; Garcia-Garcia C; Arruda MS; Curi M; Liu J; Qiao M; Velez-Sanchez P; Vargas JI
Clin Rheumatol; 2023 May; 42(5):1249-1258. PubMed ID: 36715850
[TBL] [Abstract][Full Text] [Related]
7. Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme.
Fleischmann R; Curtis JR; Charles-Schoeman C; Mysler E; Yamaoka K; Richez C; Palac H; Dilley D; Liu J; Strengholt S; Burmester G
Ann Rheum Dis; 2023 Sep; 82(9):1130-1141. PubMed ID: 37308218
[TBL] [Abstract][Full Text] [Related]
8. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme.
Cohen SB; van Vollenhoven RF; Winthrop KL; Zerbini CAF; Tanaka Y; Bessette L; Zhang Y; Khan N; Hendrickson B; Enejosa JV; Burmester GR
Ann Rheum Dis; 2021 Mar; 80(3):304-311. PubMed ID: 33115760
[TBL] [Abstract][Full Text] [Related]
9. The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan.
Yamaoka K; Tanaka Y; Kameda H; Khan N; Sasaki N; Harigai M; Song Y; Zhang Y; Takeuchi T
Drug Saf; 2021 Jun; 44(6):711-722. PubMed ID: 34041702
[TBL] [Abstract][Full Text] [Related]
10. Safety of Upadacitinib in Immune-Mediated Inflammatory Diseases: Systematic Literature Review of Indirect and Direct Treatment Comparisons of Randomized Controlled Trials.
Mysler E; Burmester GR; Saffore CD; Liu J; Wegrzyn L; Yang C; Betts KA; Wang Y; Irvine AD; Panaccione R
Adv Ther; 2024 Feb; 41(2):567-597. PubMed ID: 38169057
[TBL] [Abstract][Full Text] [Related]
11. Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Husni ME; Deodhar A; Schwartzman S; Chakravarty SD; Hsia EC; Leu JH; Zhou Y; Lo KH; Kavanaugh A
Arthritis Res Ther; 2022 Mar; 24(1):73. PubMed ID: 35313978
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies.
Baraliakos X; Ranza R; Östör A; Ciccia F; Coates LC; Rednic S; Walsh JA; Douglas K; Gao T; Kato K; Song IH; Ganz F; Deodhar A
Arthritis Res Ther; 2023 Apr; 25(1):56. PubMed ID: 37038159
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease.
Burmester GR; Panaccione R; Gordon KB; McIlraith MJ; Lacerda AP
Ann Rheum Dis; 2013 Apr; 72(4):517-24. PubMed ID: 22562972
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials.
Deodhar A; Blauvelt A; Lebwohl M; Feely M; Kronbergs A; Eberhart N; Zhu D; Inman E; Grace E; Holzkaemper T; Rahman P; Marzo-Ortega H; Papp KA; Merola JF; Gottlieb AB; Schwartzman S
Arthritis Res Ther; 2024 Feb; 26(1):49. PubMed ID: 38347650
[TBL] [Abstract][Full Text] [Related]
15. Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials.
McInnes IB; Ostor AJK; Mease PJ; Tillett W; Baraliakos X; de Vlam K; Bessette L; Lippe R; Maniccia A; Feng D; Gao T; Zueger P; Saffore C; Kato K; Song IH; Deodhar A
RMD Open; 2022 Mar; 8(1):. PubMed ID: 35332058
[TBL] [Abstract][Full Text] [Related]
16. Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
Kay J; Fleischmann R; Keystone E; Hsia EC; Hsu B; Mack M; Goldstein N; Braun J; Kavanaugh A
Ann Rheum Dis; 2015 Mar; 74(3):538-46. PubMed ID: 24344160
[TBL] [Abstract][Full Text] [Related]
17. Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
Kay J; Fleischmann R; Keystone E; Hsia EC; Hsu B; Zhou Y; Goldstein N; Braun J
J Rheumatol; 2016 Dec; 43(12):2120-2130. PubMed ID: 27803138
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials.
Curtis JR; Mariette X; Gaujoux-Viala C; Blauvelt A; Kvien TK; Sandborn WJ; Winthrop K; de Longueville M; Huybrechts I; Bykerk VP
RMD Open; 2019; 5(1):e000942. PubMed ID: 31245056
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study.
Fleischmann R; Mysler E; Bessette L; Peterfy CG; Durez P; Tanaka Y; Swierkot J; Khan N; Bu X; Li Y; Song IH
RMD Open; 2022 Feb; 8(1):. PubMed ID: 35121639
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
Ogdie A; de Vlam K; McInnes IB; Mease PJ; Baer P; Lukic T; Gruben D; Kwok K; Wang C; Hsu MA; Maniccia A
RMD Open; 2020 Feb; 6(1):. PubMed ID: 32396519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
